Potential Diagnostic Value of Abnormal Pyroptosis Genes Expression in Myelodysplastic Syndromes (MDS): A Primary Observational Cohort Study
- PMID: 38868810
- PMCID: PMC11166493
- DOI: 10.18502/ijhoscr.v18i2.15371
Potential Diagnostic Value of Abnormal Pyroptosis Genes Expression in Myelodysplastic Syndromes (MDS): A Primary Observational Cohort Study
Abstract
Background: Myelodysplastic syndromes (MDS) are determined by ineffective hematopoiesis and bone marrow cytological dysplasia with somatic gene mutations and chromosomal abnormalities. Accumulating evidence has revealed the pivotal role of NLRP3 inflammasome activation and pyroptotic cell death in the pathogenesis of MDS. Although MDS can be diagnosed with a variety of morphologic and cytogenetic tests, most of these tests have limitations or problems in practice. Materials and Methods: In the present study, we evaluated the expression of genes that form the inflammasome (NLRP3, ASC, and CASP1) in bone marrow specimens of MDS patients and compared the results with those of other leukemias to evaluate their diagnostic value for MDS. Primary samples of this observational cohort study were collected from aspiration samples of patients with myelodysplastic syndromes (27 cases) and patients with non-myelodysplastic syndrome hematological cancers (45 cases). After RNA extraction and c.DNA synthesis, candidate transcripts and housekeeping transcripts were measured by real-time PCR method (SYBER Green assay). Using Kruskal-Wallis the relative gene expressions were compared and differences with p value less than 0.05 were considered as significant. Discrimination capability, cut-off, and area under curve (AUC) of all markers were analyzed with recessive operation curve (ROC) analysis. Results: We found that Caspase-1 and ASC genes expressed at more levels in MDS specimens compared to non-MDS hematological malignancies. A relative average expression of 10.22 with a p-value of 0.001 and 1.86 with p=0.019 was detected for Caspase-1 and ASC, respectively. ROC curve analysis shows an AUC of 0.739 with p=0.0001 for Caspase-1 and an AUC of 0.665 with p=0.0139 for ASC to MDS discrimination. Conclusion: Our results show that Caspase-1 and ASC gene expression levels can be used as potential biomarkers for MDS diagnosis. Prospective studies with large sample numbers are suggested.
Keywords: ASC; Casapase1; Inflammasome; Myelodysplastic Syndromes; NLRP3; Pyroptosis.
Copyright © 2024 Tehran University of Medical Sciences.
Conflict of interest statement
The authors do not have any conflicts of interest.
Figures


Similar articles
-
Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study.Lancet Haematol. 2018 Sep;5(9):e393-e402. doi: 10.1016/S2352-3026(18)30109-1. Epub 2018 Jul 30. Lancet Haematol. 2018. PMID: 30072146 Free PMC article.
-
Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes.Blood Adv. 2021 Apr 27;5(8):2216-2228. doi: 10.1182/bloodadvances.2020003475. Blood Adv. 2021. PMID: 33890980 Free PMC article.
-
Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype.Front Oncol. 2016 Jun 16;6:151. doi: 10.3389/fonc.2016.00151. eCollection 2016. Front Oncol. 2016. PMID: 27379212 Free PMC article. Review.
-
The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype.Blood. 2016 Dec 22;128(25):2960-2975. doi: 10.1182/blood-2016-07-730556. Epub 2016 Oct 13. Blood. 2016. PMID: 27737891 Free PMC article.
-
[Research Progress on the Role of Pyroptosis in the Pathogenesis of Myelodysplastic Syndrome -Review].Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018 Jun;26(3):937-941. doi: 10.7534/j.issn.1009-2137.2018.03.052. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018. PMID: 29950247 Review. Chinese.
Cited by
-
Immune-dysregulation harnessing in myeloid neoplasms.Cancer Med. 2024 Sep;13(17):e70152. doi: 10.1002/cam4.70152. Cancer Med. 2024. PMID: 39254117 Free PMC article. Review.
References
-
- Tanaka TN, Bejar R. MDS overlap disorders and diagnostic boundaries. Blood. 2019;133(10):1086–95. - PubMed
-
- Carbuccia N, Murati A, Trouplin V, et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia. 2009;23(11):2183–6. - PubMed
-
- Font P, Loscertales J, Benavente C, et al. Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification. Ann Hematol. 2013;92(1):19–24. - PubMed
-
- Mufti GJ, McLornan DP, van de Loosdrecht AA, et al. Diagnostic algorithm for lower-risk myelodysplastic syndromes. Leukemia. 2018;32(8):1679–96. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous